HTG Announces Availability of 384/9 Gene Expression Assay
News Apr 14, 2009
HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) has announced the launch of the quantitative nuclease protection assay (qNPA™) 384/9 gene expression assay.
This new format enables the measurement of nine genes in a 384 well ArrayPlate and provides a high throughput screening and profiling method for accelerating drug discovery and development with molecular biomarkers.
This automated assay is based on HTG’s qNPA ArrayPlate technology platform, which allows researchers to investigate a larger, customized set of genes.
The technology allows pharmaceutical researchers who handle primary and secondary screening to measure gene expression levels of mRNA and miRNA in a wide variety of cell and tissue types.
“HTG’s product extension enables our clientele who are conducting primary and secondary screening to handle increasingly more complex screening requirements,” said TJ Johnson, president and CEO, HTG. “This is an extension of our existing ArrayPlate platform and we created this unique format to accommodate the diverse and dynamic needs of researchers who are looking at different numbers of genes and needed a higher plex format to do so.”
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation; HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform is flexible and designed automation-friendly; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small, yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.